Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02655055 · ClinicalTrials.gov registry record · NA
Bone Density in Voluntary Apheresis Blood Donors
A NA study, sponsored by Versiti Blood Health.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
NCT02655055: Completed NA study, sponsored by Versiti Blood Health.
NCT02655055 is a NA study that has completed, run by Versiti Blood Health. The registered enrollment target is 58 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02655055, a NA study, has completed, sponsored by Versiti Blood Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
Study Summary
A longitudinal, randomized, controlled, single-center Phase IV clinical trial will be performed to assess changes in bone mineral density (BMD) among voluntary apheresis blood donors. The primary outcome measure will be clinically significant decline in BMD at the lumbar spine assessed by dual-energy x-ray absorptiometry (DXA).
Primary Outcome
The primary outcome measure is a decline in total lumbar spine bone mineral density that exceeds the technologist's least significant change (LSC) as assessed by DXA.
Interventions
- PROCEDURE high frequency voluntary apheresis blood donation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2016-05 |
| Est. Completion | 2018-04 |
| Phase | NA |
What the finished NCT02655055 record still lists
NCT02655055 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which high frequency voluntary apheresis blood donation is the first listed.
NCT02655055 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02655055 about?
NCT02655055 is a clinical study titled "Bone Density in Voluntary Apheresis Blood Donors". A longitudinal, randomized, controlled, single-center Phase IV clinical trial will be performed to assess changes in bone mineral density (BMD) among voluntary apheresis blood donors. The primary outcome measure will be clinically significant decline in BMD at the lumbar spine assessed by dual-energ...
What is the current status of trial NCT02655055?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2016-05. Estimated completion is 2018-04.
What interventions are being tested in trial NCT02655055?
The interventions under investigation include: high frequency voluntary apheresis blood donation (PROCEDURE).
Who is sponsoring clinical trial NCT02655055?
This trial is sponsored by Versiti Blood Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02655055's enrollment target sits among peer trials
58 1256th of 2000 higher than 740 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia